Cory Renauer
Value, research analyst, biotech, small-cap

A Closer Look At Acorda's Post Commercial Stage Strategy

Acorda Therapeutics (NASDAQ:ACOR) is a commercial stage biotech company focused on neurological conditions. The company is best known for its multiple sclerosis [MS] treatments. Its two largest revenue streams are US sales of dalfampridine, a treatment intended for MS patients to walking ability, and tizanidine, a short acting manager of spasticity.

Despite recent strength across the biotech sector, Acorda has recently been trading at just over 10 times trailing twelve month earnings. With just two years of positive cash flows under its belt, generics are already taking a bite out of Acorda's tizanidine sales. Let's take a closer look at Acorda's pipeline and decide if the market has presented us a long-term opportunity, or a trap.



Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details